icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
R6tMHzhjZm2PZJD1
Listen
